

**Regd. Office :**

'Zydus Tower',  
Satellite Cross Roads,  
Ahmedabad 380 015. India.  
Phone : +91-79-2686 8100 (20 Lines)  
Fax : +91-79-2686 8337

May 16, 2013

Bombay Stock Exchange Limited  
1<sup>st</sup> Floor, P.J. Towers  
Dalal Street  
MUMBAI – 400 001

Attention: Mr. Sanjay Golecha  
Mr. Gopalkrishnan

Fax No. 022 – 22722039 / 3121

National Stock Exchange of India Ltd.  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G Block  
Bandra- Kurla Complex  
Bandra – (East)  
Mumbai – 400 051

Attention: Famroze Pochara  
Asst. Vice President

Fax No. 022 – 26598237/38

Ahmedabad Stock Exchange Limited  
Kamdhenu Complex  
Opp. Sahajanand College  
Panjra Pole,  
Ahmedabad – 380 015

Fax No. 079 - 26308877

**Re.: Press Release**

Dear Sir / Madam

We are please to announce the Day 1 launch of Zolmitriptan orally disintegrating tablets upon receiving the final approval from US FDA.


We enclose herewith a copy of press release dated May 16, 2013 under the title **“Zydus scores with the Day 1 launch of Zolmitriptan in the US”** to be released in the News Papers which gives the full details of the same.

Please bring the aforesaid news to the notice of the members of the exchange and the investors at large.

Thanking you,

Yours faithfully,

FOR CADILA HEALTHCARE LIMITED



**UPEN H. SHAH**

**Company Secretary**

**Encl.: As above.**

## **Zydus scores with the Day 1 launch of Zolmitriptan in the US**

---

Ahmedabad, 16 May 2013

Zydus Cadila announced the Day 1 launch of Zolmitriptan orally disintegrating tablets upon receiving the final approval from the US FDA. The Company is marketing the product in the strengths of 2.5 mg and 5mg in the US market. The sales of Zolmitriptan, used in the treatment of migraine, was estimated at USD 175 million in 2012 as per IMS.

The group now has 79 approvals and has so far filed 173 ANDAs since the commencement of the filing process in FY 2003-04.

\*\*\*